AI Article Synopsis
- Neoadjuvant radiochemotherapy is the standard treatment for advanced rectal cancer, but individual responses to this treatment can vary significantly.
- Researchers aimed to discover genetic markers that could predict how patients might respond to this preoperative treatment.
- The study identified two significant genetic variants, SOD2 rs4880 and IL13 rs1800925, which were associated with tumor response to treatment, suggesting the potential for personalized treatment approaches based on genetic profiles.
Article Abstract
Neoadjuvant radiochemotherapy followed by total mesorectal excision is now the standard treatment for locally advanced rectal cancer. However, tumor response to chemoradiation varies widely among individuals and cannot be determined before the final pathologic evaluation. The aim of this study was to identify germline genetic markers that could predict sensitivity or resistance to preoperative radiochemotherapy (RT-CT) in rectal cancer. We evaluated the predictive value of 128 single-nucleotide polymorphisms (SNPs) in 71 patients preoperatively treated by RT-CT. The selected SNPs were distributed over 76 genes that are involved in various cellular processes such as DNA repair, apoptosis, proliferation or immune response. The SNPs superoxide dismutase 2 (SOD2) rs4880 (P=0.005) and interleukin-13 (IL13) rs1800925 (P=0.0008) were significantly associated with tumor response to chemoradiation. These results reinforce the idea of using germline polymorphisms for personalized treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/tpj.2010.62 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!